ヒト免疫不全ウイルス（HIV）におけるデジタルマーケティング動向

2021年4月から2022年3月までの米国におけるHIV患者向けブランドサイト全体では、GileadのBiktarvy.comが約380万人の訪問を達成し、次いでViiVのDovato.com、GileadのDescovy.comの順となりました。これらのサイトへのトラフィックは、直接のソースから発生したものが最も多く、次いでリファーラルとなっています。Descovy、Cabenuva、Truvada、Pifeltroなどのブランドサイトでは、直接アクセスが同程度に多く（53%～57%）、JanssenのSymtuza.comは最も少ない（34%）という結果になりました。

当レポートでは、患者や医療従事者（HCP）向けのブランドウェブサイト、モバイルアプリ、ソーシャルメディアアカウントなど、ヒト免疫不全ウイルス（HIV）関連の製薬企業の主要なデジタルマーケティング指標を評価しています。指標には、ウェブサイトのトラフィック量、エンゲージメント、ソース、デジタルディスプレイ広告（DDA）、有料検索エンジン最適化（SEO）、モバイルアプリのダウンロード、ソーシャルメディアへの投稿のインタラクションが含まれます。国別では、米国、4EU（イタリア、フランス、ドイツ、スペイン）、英国、カナダ（EUCAN）が含まれます。

目次

目次

• エグゼクティブサマリー
• 米国の患者ブランドのウェブサイト
• 米国のHCPブランドのWebサイト
• 米国のデジタルディスプレイ広告と検索エンジン最適化
• 米国のモバイルアプリとソーシャルメディア
• EUCANブランドのウェブサイト
• EUCANモバイルアプリとソーシャルメディア

付録

• 調査手法
• 著者について
• カスタマーサポート

List of Tables

Gilead's Biktarvy.com achieved the highest traffic across branded HIV patient sites in the US from April 2021 to March 2022, with about 3,800,000 visits, followed by ViiV's Dovato.com and Gilead's Descovy.com. The highest proportion of traffic to these sites originated from direct sources, followed by referrals. Websites for several brands, including Descovy, Cabenuva, Truvada, and Pifeltro, had similar levels of high direct traffic (53-57%), while Janssen's Symtuza.com had the lowest (34%).

For patient branded sites, Gilead spent the most on DDA for Biktarvy.com at $20.5 million, followed by Gilead's Descovy.com at $3.6 million and ViiV's Dovato.com at $2.3 million. Descovy.com was supported by the most paid keywords at approximately 10,200 keywords, followed by Biktarvy.com at about 5,900 keywords.

For branded HCP sites in the US, Gilead's Descovyhcp.com had the highest number of visits at approximately 250,000 visits, followed by Gilead's Biktarvyhcp.com (198,500 visits) and ViiV's Dovatohcp.com (184,000 visits). The highest proportion of traffic these sites originated from direct and organic sources. ViiV's Rukobiahcp.com and Dovatohcp.com had the highest proportion of traffic from direct searches (66% and 61%, respectively). Gilead spent the most on DDA for Biktarvyhcp.com at approximately $212,000, followed by its Descovyhcp.com at approximately $67,000.

Between April 2021 and March 2022, the top 20 social media HIV posts by interaction from pharma were from Gilead COMPASS Initiative Twitter and Instagram, ViiV Healthcare's Instagram, and Gilead Science's Twitter. Gilead's HIV Answers is the only app detected from pharma is the US and had an estimated 730 downloads in 2021.

Most branded websites in EUCAN are in Canada and are patient-directed. Few generated notable traffic between April 2021 and March 2022. Gilead's Bitarvy.ca and Descovy.ca achieved the highest traffic, with about 52,000 visits and 27,000 visits, respectively.

Between April 2021 and March 2022, most of the top 20 social media HIV posts by interaction in EUCAN from pharma were from MSD Europe's Twitter account. No HIV apps from pharma with notable downloads were detected in EUCAN.

Scope

• This report assesses key digital marketing metrics of pharma assets in human immunodeficiency virus (HIV), including branded websites for patients and healthcare professionals (HCPs), mobile apps, and social media accounts.
• Metrics include website traffic volume, engagement, and source, digital display advertising (DDA), paid search engine optimization (SEO), mobile app downloads, and social media post interaction.
• Countries include the US, 4EU (Italy, France, Germany, and Spain), the UK, and Canada (EUCAN).

Reasons to Buy

• Understand the digital marketing competitive landscape in HIV, with a view of leading patient and HCP branded assets across different regions.
• See what tactics pharma companies are using to drive traffic to their HIV branded assets for patient and HCPs, such as DDA and paid SEO.
• Understand what sources of website traffic are generating the most visits to these assets, such as paid SEO, social media, or organic searches.
• Compare top branded assets for patients by how they address and support different patient needs.
• See what pharma social media accounts in HIV are the most active and achieving the most engagement.
• See leading mobile app offerings in HIV from pharma across different regions.

Table of Contents

Table of Contents

• Executive Summary
• US Patient Branded Websites
• US HCP Branded Websites
• US Digital Display Advertising and Search Engine Optimization
• US Mobile Apps and Social Media
• EUCAN Branded Websites
• EUCAN Mobile Apps and Social Media

Appendix

• Methodology
• About the Authors
• Contact Us